Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Implication: If you or your family have a history of MTC or multiple endocrine neoplasia type 2, retatrutide is not recommended
Our dedication to FDA-approved medications ensures that at Klinic in Duluth, we focus on the highest quality GLP-1 options like Wegovy and steer clear of compounded versions
98 , E664E671 (2013)
Benefit-risk profile As the research on retatrutide continues to evolve, healthcare providers and individuals considering this treatment option can expect a deeper understanding of the medications side effect profile
Retatrutide (LY3437943) is Eli Lilly's investigational triple-agonist that targets three receptors: GLP-1 , GIP , and glucagon
The first week is not the time to judge whether Retatrutide will work for you
US$ 26.96
US$ 21.24
US$ 22.13
US$ 22.30
US$ 28.87
US$ 22.10
US$ 26.42
US$ 26.84
